Analysts Expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Post $1.31 Earnings Per Share

Equities analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce earnings per share (EPS) of $1.31 for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $1.12 and the highest estimate coming in at $1.49. Lexicon Pharmaceuticals reported earnings per share of ($0.26) in the same quarter last year, which would indicate a positive year over year growth rate of 603.8%. The business is expected to report its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($0.17) per share for the current year, with EPS estimates ranging from ($1.89) to $0.73. For the next fiscal year, analysts anticipate that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.15) to ($1.49). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.13). The company had revenue of $9.68 million for the quarter, compared to analysts’ expectations of $28.52 million. Lexicon Pharmaceuticals’s revenue was down 29.9% compared to the same quarter last year. During the same period last year, the business posted ($0.33) EPS.



A number of equities research analysts recently commented on the stock. Gabelli raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Wednesday, September 11th. Citigroup reduced their target price on shares of Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, July 30th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 19th. Finally, ValuEngine downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $6.70.

In other news, Director Christopher J. Sobecki purchased 25,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the acquisition, the director now directly owns 112,493 shares in the company, valued at $286,857.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Lonnel Coats purchased 50,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $3.13 per share, with a total value of $156,500.00. Following the completion of the acquisition, the chief executive officer now owns 127,639 shares in the company, valued at $399,510.07. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 289,749 shares of company stock worth $618,230. 6.40% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of LXRX. First Manhattan Co. increased its position in Lexicon Pharmaceuticals by 7.3% in the 2nd quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock worth $18,555,000 after buying an additional 201,393 shares during the period. Voloridge Investment Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $105,000. Pictet Asset Management Ltd. grew its position in Lexicon Pharmaceuticals by 13.4% in the second quarter. Pictet Asset Management Ltd. now owns 665,776 shares of the biopharmaceutical company’s stock valued at $4,188,000 after acquiring an additional 78,926 shares during the period. Price T Rowe Associates Inc. MD grew its position in Lexicon Pharmaceuticals by 77.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 26,900 shares during the period. Finally, Morgan Stanley grew its position in Lexicon Pharmaceuticals by 158.0% in the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 119,611 shares during the period. Hedge funds and other institutional investors own 98.87% of the company’s stock.

LXRX traded down $0.16 during trading on Thursday, hitting $3.20. The stock had a trading volume of 1,353,803 shares, compared to its average volume of 3,491,887. Lexicon Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $11.51. The firm has a market capitalization of $378.33 million, a P/E ratio of -2.81 and a beta of 0.75. The company’s 50-day moving average price is $1.76 and its 200 day moving average price is $4.86.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.